BioNTech Outlines 2025 Strategy at J.P. Morgan Conference
Ticker: BNTX · Form: 6-K · Filed: Jan 14, 2025 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: strategy, conference, biotech
TL;DR
BioNTech laid out its 2025 game plan at JPM conference, focusing on pipeline and growth.
AI Summary
On January 14, 2025, BioNTech SE presented its 2025 strategic priorities at the 43rd annual J.P. Morgan Healthcare Conference. The company, headquartered in Mainz, Germany, is focused on advancing its pipeline and expanding its commercial footprint.
Why It Matters
This filing provides insight into BioNTech's forward-looking plans, which could impact its future product development and market position in the biotechnology sector.
Risk Assessment
Risk Level: low — The filing is a routine corporate update and does not contain significant new financial information or material adverse events.
Key Players & Entities
- BioNTech SE (company) — Registrant
- January 14, 2025 (date) — Date of presentation
- J.P. Morgan Healthcare Conference (event) — Conference where priorities were presented
- Mainz, Germany (location) — Company headquarters
FAQ
What are BioNTech SE's main strategic priorities for 2025?
BioNTech SE outlined its 2025 strategic priorities at the 43rd annual J.P. Morgan Healthcare Conference, focusing on advancing its pipeline and expanding its commercial footprint.
When did BioNTech SE present its 2025 strategic priorities?
BioNTech SE presented its 2025 strategic priorities on January 14, 2025.
Where was the J.P. Morgan Healthcare Conference held?
The filing does not specify the location of the J.P. Morgan Healthcare Conference, only that BioNTech SE presented there.
What is BioNTech SE's SEC file number?
BioNTech SE's SEC file number is 001-39081.
What form is this SEC filing?
This SEC filing is a Form 6-K.
Filing Stats: 248 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2025-01-14 06:58:45
Filing Documents
- form6-kjpmpresentationpr14.htm (6-K) — 15KB
- a99_1bntxjpmorganhealthcar.htm (EX-99.1) — 32KB
- a99_2biontechjpmx2025.htm (EX-99.2) — 41KB
- a99_2biontechjpmx2025001.jpg (GRAPHIC) — 75KB
- a99_2biontechjpmx2025002.jpg (GRAPHIC) — 303KB
- a99_2biontechjpmx2025003.jpg (GRAPHIC) — 78KB
- a99_2biontechjpmx2025004.jpg (GRAPHIC) — 128KB
- a99_2biontechjpmx2025005.jpg (GRAPHIC) — 119KB
- a99_2biontechjpmx2025006.jpg (GRAPHIC) — 118KB
- a99_2biontechjpmx2025007.jpg (GRAPHIC) — 108KB
- a99_2biontechjpmx2025008.jpg (GRAPHIC) — 84KB
- a99_2biontechjpmx2025009.jpg (GRAPHIC) — 122KB
- a99_2biontechjpmx2025010.jpg (GRAPHIC) — 118KB
- a99_2biontechjpmx2025011.jpg (GRAPHIC) — 90KB
- a99_2biontechjpmx2025012.jpg (GRAPHIC) — 84KB
- a99_2biontechjpmx2025013.jpg (GRAPHIC) — 92KB
- a99_2biontechjpmx2025014.jpg (GRAPHIC) — 123KB
- a99_2biontechjpmx2025015.jpg (GRAPHIC) — 90KB
- a99_2biontechjpmx2025016.jpg (GRAPHIC) — 128KB
- a99_2biontechjpmx2025017.jpg (GRAPHIC) — 67KB
- a99_2biontechjpmx2025018.jpg (GRAPHIC) — 120KB
- a99_2biontechjpmx2025019.jpg (GRAPHIC) — 95KB
- a99_2biontechjpmx2025020.jpg (GRAPHIC) — 129KB
- a99_2biontechjpmx2025021.jpg (GRAPHIC) — 151KB
- a99_2biontechjpmx2025022.jpg (GRAPHIC) — 133KB
- a99_2biontechjpmx2025023.jpg (GRAPHIC) — 106KB
- a99_2biontechjpmx2025024.jpg (GRAPHIC) — 94KB
- a99_2biontechjpmx2025025.jpg (GRAPHIC) — 125KB
- a99_2biontechjpmx2025026.jpg (GRAPHIC) — 94KB
- a99_2biontechjpmx2025027.jpg (GRAPHIC) — 144KB
- a99_2biontechjpmx2025028.jpg (GRAPHIC) — 109KB
- a99_2biontechjpmx2025029.jpg (GRAPHIC) — 105KB
- a99_2biontechjpmx2025030.jpg (GRAPHIC) — 23KB
- a99_2biontechjpmx2025031.jpg (GRAPHIC) — 89KB
- a99_2biontechjpmx2025032.jpg (GRAPHIC) — 143KB
- image_0.jpg (GRAPHIC) — 102KB
- 0001776985-25-000002.txt ( ) — 5172KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On January 14, 2025, BioNTech SE outlined its 2025 strategic priorities at the 43rd annual J.P. Morgan Healthcare Conference. The press release and presentation are attached as Exhibits 99.1 and 99.2, respectively. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Jens Holstein By s Dr. Sierk Poetting Name Jens Holstein Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date January 14, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech provides business and pipeline updates at 43rd annual J.P. Morgan Healthcare Conference 99.2 Presentation